BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program.
Dae-Hwan KimDuanchen SunWilliam K StorckKatherine Welker LengChelsea JenkinsDaniel J ColemanDavid SampsonXiangnan GuanAnbarasu KumaraswamyEva S RodanskyJoshua A UrrutiaJacob A SchwartzmanChao ZhangHimisha BeltranMark P LabrecqueColm MorrisseyJared M LucasIlsa M ColemanPeter S NelsonEva CoreySamuel K HandelmanJonathan Z SextonRahul AggarwalWassim AbidaFelix Y FengEric J SmallDaniel E SprattArmand BankheadArvind RaoEmily M GesnerSarah AttwellSanjay LakhotiaEric CampeauJoel A YatesZheng XiaJoshi J AlumkalPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
E2F1 and BRD4 are critical for activating an AR-repressed, t-NEPC lineage plasticity program. BETi is a promising approach to block this program.